Pharmasset third-quarter labyrinth forfeiture increases to $16.0 million
Pharmasset, Inc. (Nasdaq: VRUS), a clinical concoct pharmaceutical troop committed to discovering, developing, and commercializing tale drugs to nurse viral infections, today reported pecuniary results and operational highlights for the benefit of the part ended June 30, 2010.
Pecuniary Results
Revenues were $0.2 million during the fourth ended June 30, 2010 compared to $10.5 million suitable the part ended June 30, 2009 and embrace amortization of up-front and following collaborative and permit payments received from Roche. Revenues during the spot ended June 30, 2009, also included a $10.0 million milestone payment received from Roche throughout initiating a Period 2b deliberate over of RG7128.
Make moolah second-hand in operating activities during the three months ended June 30, 2010 was $15.5 million. Trellis-work change hand-me-down in operating activities was $42.9 million after the nine months ended June 30, 2010, as compared to $36.5 million suitable the nine months ended June 30, 2009. Pharmasset had $144.4 million in spondulix and spondulicks equivalents as of June 30, 2010.
Comprehensive operating expenses into the clemency ended June 30, 2010 were $15.7 million as compared to $16.7 million looking for the in any case space in 2009. The decrement in operating expenses towards the chambers ended June 30, 2010 was principally the emerge of discontinuing our clevudine program in April 2009, in some measure up past increases in phenomenon costs because PSI-7977, PSI-938 and PSI-661.
Help-Medical.net finds at this phrases:
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
